Trial Profile
A Phase I, Prospective, Randomized, Open Label, Observer-Blind, Single Center Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an Inactivated H5N1 Influenza Vaccine Produced in Madin-Darby Canine Kidney (MDCK) Cells
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs AT 301 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions
- Sponsors Medigen Biotechnology Corporation
- 05 Sep 2012 New trial record